Month: June 2026

  • Macular Degeneration Treatment Market Growth Outlook Indicating Expansion To $20.74 Billion By 2030

    Macular Degeneration Treatment Market Growth Outlook Indicating Expansion To $20.74 Billion By 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Increase In Market Value Is Predicted For The Macular Degeneration Treatment Market During The 2026–2030 Period?

    The macular degeneration treatment market size has seen significant expansion in recent years. It is projected to grow from $12.38 billion in 2025 to $13.81 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.5%. The market’s past growth can be attributed to factors such as an aging global population, an increased prevalence of age-related macular degeneration, the clinical success of anti-VEGF injections, improved ophthalmic diagnostic capabilities, and growing access to specialized eye care services.

    The macular degeneration treatment market is projected to experience swift expansion in the coming years. This market is forecast to reach $20.74 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. Factors contributing to this growth during the projection period include a globally increasing elderly population, greater investment in sophisticated retinal treatments, an intensified focus on managing early-stage AMD, wider embrace of gene and regenerative therapies, and elevated healthcare expenditure on vision-related care. Key trends anticipated for the forecast timeframe encompass an increased emphasis on early diagnosis and managing disease progression, wider uptake of anti-VEGF therapies, a rising need for treatments aimed at long-term vision preservation, the proliferation of minimally invasive treatment choices, and enhanced public awareness regarding age-related eye conditions.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

    What Important Drivers Are Powering The Macular Degeneration Treatment Market Growth?

    The rising prevalence of retinal disorders is anticipated to propel the growth of the macular degeneration treatment market. These conditions affect vital tissue, disrupting how individuals process visual information and leading to distorted or absent vision. For instance, according to the American Academy of Ophthalmology, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, a general term used to describe a group of eye disorders, by 2050, with the highest numbers observed among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). Hispanic men represent the largest demographic group affected. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment market.

    Which Segment Groups Define The Macular Degeneration Treatment Market Landscape?

    The macular degeneration treatment market covered in this report is segmented –

    1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD

    2) By Route of Administration: Oral, Injectable, Other Routes of Administration

    3) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals

    Subsegments:

    1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments

    2) By Intermediate AMD: Regular Disease Monitoring and Imaging Surveillance, Risk-Factor Management and Lifestyle Modification

    3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

    Which Trends Are Expected To Shape The Macular Degeneration Treatment Market?

    Leading companies in the macular degeneration treatment market are concentrating on developing biosimilar medications for age-related macular degeneration (AMD) to broaden access to effective therapeutic options. Biosimilars are biological medical products that bear a high degree of resemblance to an already approved reference product, lacking any clinically relevant distinctions in terms of their safety, purity, or potency. For instance, in May 2024, Biocon Biologics Ltd, an Indian-based company, and Samsung Bioepis Co. Ltd, a South Korea-based company, obtained FDA Approvals for Yesafili and Opuviz, which are two novel biosimilars. Both of these biosimilars work by inhibiting vascular endothelial growth factor (VEGF), a factor responsible for abnormal blood vessel proliferation within the eye. This mechanism assists in preventing vision loss linked to conditions like AMD and diabetic retinopathy. The FDA’s approval process encompassed comparative studies that indicated Yesafili and Opuviz possess no notable differences in their efficacy or safety when compared to Eylea. These investigations involved thorough evaluations of the biosimilars’ pharmacokinetics and immunogenicity.

    Which Firms Are Competing In The Macular Degeneration Treatment Market?

    Major companies operating in the macular degeneration treatment market are F Hoffmann La Roche Ltd, Regeneron Pharmaceuticals Inc, Novartis AG, Bayer AG, Allergan Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio Inc, Aerie Pharmaceuticals Inc, Kodiak Sciences Inc, Neurotech Pharmaceuticals Inc, Regenxbio Inc, Adverum Biotechnologies Inc, Applied Genetic Technologies Corp, 4D Molecular Therapeutics Inc, GenSight Biologics SA, Nanoscope Therapeutics Inc, Annexon Inc, Ocular Therapeutix Inc, Graybug Vision Inc

    Access The Complete Macular Degeneration Treatment Market Report:

    https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

    Which Region Stands As The Largest Contributor To The Macular Degeneration Treatment Market?

    North America was the largest region in the macular degeneration treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Macular Degeneration Treatment Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp

    Browse Through More Reports Similar to the Global Macular Degeneration Treatment Market 2026, By The Business Research Company

    Antibiotics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

    Peptide Antibiotics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

    Veterinary Antibiotics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/veterinary-antibiotics-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Macrolide Antibiotics Market Anticipated To Grow To $106.69 Billion By 2030 At 10% CAGR

    Global Macrolide Antibiotics Market Anticipated To Grow To $106.69 Billion By 2030 At 10% CAGR

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Will The Market Size Of The Macrolide Antibiotics Market Progress Through 2030?

    The macrolide antibiotics market size has shown rapid expansion in recent years. It is projected to increase from $65.42 billion in 2025 to $72.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.2%. This historical growth can be attributed to several factors, including the widespread prevalence of bacterial respiratory infections, the long-standing clinical use of erythromycin and azithromycin, broad physician familiarity with macrolides, the expansion of hospital and outpatient antibiotic use, and their strong efficacy against gram-positive pathogens.

    The macrolide antibiotics market size is poised for rapid expansion in the coming years, expected to reach $106.7 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This anticipated growth can be attributed to several factors, including the increasing incidence of community-acquired infections, the expansion of outpatient and ambulatory care services, a heightened demand for cost-effective generic antibiotics, an intensified focus on antimicrobial resistance management, and broadening healthcare access in emerging economies. Key trends influencing the forecast period include a sustained demand for broad-spectrum antibiotics, their increasing application in respiratory tract infections, a growing preference for oral antibiotic formulations, the proliferation of generic macrolide antibiotics, and a stronger emphasis on antibiotic stewardship programs.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16472&type=smp

    Which Major Factors Are Contributing To The Development Of The Macrolide Antibiotics Market?

    The macrolide antibiotics market is anticipated to grow as a result of the rising occurrence of skin infections. A skin infection is defined as a condition where detrimental microorganisms penetrate the skin, leading to inflammation and frequently accompanied by symptoms such as redness, swelling, and pain. The proliferation of skin infections can be attributed to elements like inadequate hygiene practices, compromised immune systems, contact with environmental contaminants, antibiotic resistance, and insufficient wound care. Macrolide antibiotics are regularly prescribed for bacterial skin infections, including those caused by Staphylococcus aureus or Streptococcus pyogenes, especially in cases of penicillin allergy or resistance. For instance, in August 2023, Skin Health Institute Inc., an Australia-based non-profit organization, stated that psoriasis impacts an estimated 2–3% of the population in Australia, highlighting it as a widespread skin ailment. Consequently, the increasing prevalence of skin infections is fueling the expansion of the macrolide antibiotics market.

    What Key Segment Areas Are Included In The Macrolide Antibiotics Market Assessment?

    The macrolide antibiotics market covered in this report is segmented –

    1) By Drugs: Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, Telithromycin

    2) By Indication: Respiratory Tract Infections, Skin Infections, Sexually Transmitted Infections, Gastrointestinal Infections, Other Indications

    3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administrations

    4) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

    5) By End User: Hospital, Dermatology Clinic, Clinic, Ambulatory Centre

    Subsegments:

    1) By Azithromycin: Oral Tablets, Oral Suspension, Injection

    2) By Clarithromycin: Immediate-Release Tablets, Extended-Release Tablets, Oral Suspension

    3) By Erythromycin: Tablets, Capsules, Topical Solution, Injection

    4) By Fidaxomicin: Oral Tablets, Oral Suspension

    5) By Telithromycin: Oral Tablets, Oral Film-Coated Tablets

    Which Trends Are Affecting The Macrolide Antibiotics Market Framework?

    Major companies operating in the macrolide antibiotics market are concentrating on developing innovative products like ketolide antibiotics. These are designed to overcome antimicrobial resistance and shorten treatment durations, aiming to improve patient adherence and alleviate the healthcare burden. Ketolide antibiotics, derived from macrolides, are intended to treat bacterial infections, including those resistant to standard macrolides, by inhibiting bacterial protein synthesis. This helps in combating resistant strains and enhancing treatment efficacy. For instance, in November 2024, Wockhardt Ltd., an India-based pharmaceutical company, soft-launched Nafithromycin, marketed under the brand name Miqnaf. This innovative lactone-ketolide macrolide antibiotic targets drug-resistant community-acquired bacterial pneumonia. The product, a novel small-molecule macrolide/ketolide (nafithromycin), is formulated for oral dosing as an ultra-short, once-daily, three-day course. It was developed to highly concentrate in lung tissue, exhibit greater in vitro potency against some azithromycin-resistant strains, and provide a simplified regimen to improve compliance and reduce overall antibiotic exposure.

    Who Are The Major Companies Operating In The Macrolide Antibiotics Market?

    Major companies operating in the macrolide antibiotics market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Viatris Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Limited, Aurobindo Pharma Limited, Dr Reddys Laboratories Limited, Wockhardt Limited, Hikma Pharmaceuticals PLC, Sandoz Group AG

    Access The Complete Macrolide Antibiotics Market Report:

    https://www.thebusinessresearchcompany.com/report/macrolide-antibiotics-global-market-report

    What Is The Largest Regional Market In The Macrolide Antibiotics Market?

    North America was the largest region in the macrolide antibiotics market in 2025. The regions covered in the macrolide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Macrolide Antibiotics Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=16472&type=smp

    Browse Through More Reports Similar to the Global Macrolide Antibiotics Market 2026, By The Business Research Company

    Rna Sequencing Services Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rna-sequencing-services-global-market-report

    Rna Targeting Small Molecules Therapeutics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

    Microrna Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/microrna-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Lupus Therapeutics Market Future Analysis Covering Industry Shifts And Growth Potential

    Lupus Therapeutics Market Future Analysis Covering Industry Shifts And Growth Potential

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Expected Market Size Of The Lupus Therapeutics Market In 2026 And How Much Will It Reach By 2030?

    The lupus therapeutics market has experienced substantial growth in recent years. It is anticipated to expand from $2.98 billion in 2025 to $3.23 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.7%. This historical growth can be linked to the increasing prevalence of systemic lupus erythematosus, the widespread application of corticosteroids and antimalarial drugs, improved clinical diagnosis of autoimmune disorders, the expansion of hospital-based rheumatology care, and growing patient awareness concerning lupus symptoms.

    The lupus therapeutics market is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach a value of $4.34 billion, growing at a compound annual growth rate (CAGR) of 7.7%. This projected growth can be attributed to several factors, including increased investment in biologic drug development, a rising demand for steroid-sparing therapies, augmented funding for autoimmune disease research, wider availability of specialty rheumatology clinics, and greater healthcare spending on chronic autoimmune conditions. Key trends anticipated during this period involve the increasing uptake of biologic and targeted treatments, a heightened focus on sustained disease management, a greater emphasis on individualized lupus care, the broadening of combination therapy strategies, and improved awareness regarding early lupus diagnosis and intervention.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16471&type=smp

    What Key Growth Drivers Are Influencing The Lupus Therapeutics Market?

    Heightened research and development efforts are anticipated to drive the expansion of the lupus therapeutics market in the future. These activities encompass structured investigations and experiments focused on enhancing understanding, technology, or product creation across diverse sectors. The surge in R&D is frequently motivated by the demand for new solutions, technological progress, confronting new difficulties, betterment of health results, and stimulating economic prosperity via scientific and technological breakthroughs. Such endeavors contribute to advancing lupus therapeutics through the identification of novel treatments, enhancement of current therapies, and elucidation of the disease’s fundamental mechanisms. For example, a March 2023 report from the U.S. federal legislative agency, the Congressional Research Service, highlighted that the President’s FY2024 budget plan designates around $209.7 billion for research and development (R&D). This constitutes an increase of $8.9 billion (4.4%) compared to the FY2023 estimated figure of $200.8 billion. After adjusting for inflation to FY2024 dollars, this proposed amount shows a 2.4% rise in constant dollars when benchmarked against the actual level of FY2023. Consequently, the expanding scope of research and development efforts is propelling the expansion of the lupus therapeutics market.

    How Is Segment Classification Applied In The Lupus Therapeutics Market?

    The lupus therapeutics market covered in this report is segmented –

    1) By Disease Type: Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, Neonatal Lupus

    2) By Treatment Type: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Biologics, Antimalarial Drugs, Corticosteroids, Other Treatment Types

    3) By Route Of Administration: Oral, Subcutaneous, Intravenous, Other Routes Of Administration

    4) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users

    Subsegments:

    1) By Systemic Lupus Erythematosus (SLE): Mild SLE, Moderate SLE, Severe SLE

    2) By Cutaneous Lupus Erythematosus: Acute Cutaneous Lupus, Subacute Cutaneous Lupus, Chronic Cutaneous Lupus (Including Discoid Lupus)

    3) By Drug-Induced Lupus Erythematosus: Medications Known To Cause Drug-Induced Lupus, Hydralazine, Procainamide, Isoniazid

    4) By Neonatal Lupus: Heart-Related Neonatal Lupus, Skin-Related Neonatal Lupus

    What Trends Are Influencing The Lupus Therapeutics Market?

    Major companies operating in the lupus therapeutics market are intensely focused on advancing blood tests that incorporate predictive artificial intelligence to improve both diagnostic accuracy and treatment efficacy. These blood tests, utilizing predictive artificial intelligence, are defined as diagnostic instruments that employ AI algorithms to analyze biomarkers within blood samples, thus forecasting disease outcomes or treatment responses with enhanced precision. A notable example occurred in March 2024, when AMPEL BioSolutions LLC, a US-based precision medicine company, launched its LuGENE blood test. This innovative test uses predictive artificial intelligence to predict lupus flares and identify specific drug targets from gene expression data. The LuGENE test aims to transform the management of lupus, an autoimmune disease, by offering personalized treatment options to patients. It functions by pinpointing real-time abnormalities in gene expression that contribute to inflammation and immune system dysfunction, which can then be effectively targeted by medication.

    Which Companies Are Influencing The Lupus Therapeutics Market?

    Major companies operating in the lupus therapeutics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Roche Holdings Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Ltd, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited

    Access The Complete Lupus Therapeutics Market Report:

    https://www.thebusinessresearchcompany.com/report/lupus-therapeutics-global-market-report

    Which Region Contributes The Most To The Lupus Therapeutics Market?

    North America was the largest region in the lupus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lupus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Lupus Therapeutics Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=16471&type=smp

    Browse Through More Reports Similar to the Global Lupus Therapeutics Market 2026, By The Business Research Company

    Systemic Lupus Erythematosus Treatment Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/systemic-lupus-erythematosus-treatment-global-market-report

    Rheumatology Therapeutics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

    Anti Inflammatory Therapeutics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Lupus Nephritis Market Analysis Reflecting Expansion Trends And Industry Performance

    Lupus Nephritis Market Analysis Reflecting Expansion Trends And Industry Performance

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Market Size Is Forecasted For The Lupus Nephritis Market By 2030 Based On Its 2026 Value?

    The lupus nephritis market size has shown significant expansion in recent years. It is anticipated to increase from $2.08 billion in 2025 to $2.24 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.7%. This growth in the historic period is attributable to the increasing prevalence of systemic lupus erythematosus, advancements in kidney biopsy and diagnostic practices, the widespread use of corticosteroids in treatment, the expansion of hospital-based nephrology care, and heightened awareness of autoimmune kidney diseases.

    The lupus nephritis market size is poised for significant expansion in the coming years. It is projected to reach $2.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This growth over the forecast period is propelled by factors such as increasing investment in biologic drug development, a greater emphasis on early intervention to prevent kidney failure, the rising adoption of combination therapy regimens, the expansion of specialty nephrology clinics, and increased healthcare spending dedicated to managing autoimmune diseases. Prominent trends anticipated during this period include a heightened focus on early diagnosis and disease monitoring, the growing uptake of immunosuppressive and biologic therapies, an increasing push towards personalized treatment approaches, the broadening of long-term disease management strategies, and rising awareness regarding autoimmune kidney complications.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

    Which Core Factors Are Supporting The Expansion Of The Lupus Nephritis Market?

    The lupus nephritis market is anticipated to expand, driven by the rising occurrence of genetic predisposition. Genetic predisposition describes inherited genetic characteristics that elevate an individual’s susceptibility to specific diseases or conditions. This increase in genetic predisposition stems from elements like inheritance patterns, environmental factors, and genetic mutations. Its growing prevalence significantly contributes to the onset of lupus nephritis, highlighting how inherited genetic elements influence autoimmune conditions, especially those impacting renal function. For example, in October 2024, the UK-based national charity, the Cystic Fibrosis Trust, reported via its UK CF Registry that registered patients increased from 11,148 in 2022 to 11,318 in 2024, marking a 1.52% rise in individuals with cystic fibrosis (CF). Consequently, the rising incidence of genetic predisposition is fueling the expansion of the lupus nephritis market.

    What Are The Core Segment Classifications In The Lupus Nephritis Market?

    The lupus nephritis market covered in this report is segmented –

    1) By Stage: Class 1, Class 2, Class 3, Other Stages

    2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs

    3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

    4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

    5) By End-User: Hospitals, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis

    2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition

    3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation

    4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

    Which Trends Are Guiding The Development Of The Lupus Nephritis Market?

    Major companies active in the lupus nephritis market are concentrating on developing sophisticated second-generation calcineurin inhibitors, aiming to elevate treatment efficacy and improve long-term kidney health outcomes for patients. These second-generation calcineurin inhibitors are applied in lupus nephritis to diminish inflammation and avert kidney damage through the modulation of immune responses. For instance, in September 2024, Aurinia Pharmaceuticals Inc., a Canada-based commercial-stage biopharmaceutical company, announced that LUPKYNIS (voclosporin) received approval from the Japanese Ministry of Health, Labour, and Welfare for the management of lupus nephritis. This authorization permits voclosporin to be administered in conjunction with mycophenolate mofetil (MMF), based on data from the AURORA Clinical Program which demonstrated its safety and effectiveness. The approval represents a crucial achievement in expanding therapeutic alternatives for lupus nephritis patients in Japan, leading to improved disease management and patient outcomes.

    Who Are The Companies Shaping The Lupus Nephritis Market Landscape?

    Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc

    Access The Complete Lupus Nephritis Market Report:

    https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

    Which Regional Market Leads The Lupus Nephritis Market?

    Asia-Pacific was the largest region in the lupus nephritis market in 2025. The regions covered in the lupus nephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Lupus Nephritis Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=22044&type=smp

    Browse Through More Reports Similar to the Global Lupus Nephritis Market 2026, By The Business Research Company

    Cutaneous Lupus Erythematosus Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cutaneous-lupus-erythematosus-global-market-report

    Lupus Therapeutics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/lupus-therapeutics-global-market-report

    Kidney Disease Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Lung Cancer Surgery Market Revenue Expected To Reach $6.73 Billion By 2030

    Global Lung Cancer Surgery Market Revenue Expected To Reach $6.73 Billion By 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Is The Market Value Of The Lung Cancer Surgery Market Projected To Expand During 2026–2030?

    The lung cancer surgery market size has experienced significant expansion over recent years. It is anticipated to grow from $5.33 billion in 2025 to $5.6 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.1%. The increase observed in the past can be credited to rising lung cancer incidence rates, the expansion of surgical capacities in hospitals, the availability of proficient thoracic surgeons, the increasing use of video-assisted thoracoscopic surgery, and enhanced awareness regarding early-stage lung cancer treatment.

    The lung cancer surgery market is anticipated to experience consistent expansion in the coming years. It is projected to achieve a value of $6.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.7%. This growth over the forecast period can be attributed to the increasing integration of robotic surgery platforms, a rising demand for precise surgical outcomes, the expansion of specialized cancer care centers, growing investments in surgical technology, and the increasing adoption of enhanced recovery after surgery protocols. Major trends during this period include a greater uptake of minimally invasive surgical techniques, the rising use of robotic-assisted thoracic surgery, a growing preference for lung-preserving procedures, an expansion in the utilization of advanced surgical instruments, and an enhanced focus on post-surgical recovery outcomes.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25816&type=smp

    What Are The Main Drivers Accelerating The Growth Of The Lung Cancer Surgery Market?

    The rising occurrence of lung cancer is projected to drive the expansion of the lung cancer surgery market in the future. This condition involves the unchecked multiplication of atypical cells within one or both lungs, potentially disrupting their regular operation. This escalating prevalence of lung cancer stems from extended exposure to air pollution, particularly fine particulate matter. Such microscopic particles are capable of reaching deep into the lungs, triggering inflammation, harming cells, and inducing genetic changes that may result in cancer formation. Surgical intervention for lung cancer contributes to lowering the mortality rate associated with the disease by facilitating the prompt excision of cancerous tumors before their potential dissemination or advancement. As an illustration, in June 2025, data from the Centers for Disease Control and Prevention, a US-based federal government agency, indicated that in 2023, lung cancer caused 131,584 deaths in the United States, subsequent to 218,893 newly reported cases in 2022. Consequently, the increasing incidence of lung cancer is stimulating the expansion of the lung cancer surgery market.

    How Is The Lung Cancer Surgery Market Structured Across Different Market Segments?

    The lung cancer surgery market covered in this report is segmented –

    1) By Surgical Approach: Thoracotomy, Minimally Invasive Surgeries

    2) By Procedure: Lobectomy, Segmentectomy, Pneumonectomy, Sleeve Resection, Extended Reserction

    3) By Product: Thoracoscopes, Mediastinoscopes, Bronchoscopes, Robotic-Assistes Thoracic Surgery Systems, Surgical Staplers, Surgical Energy Instruments, Advanced Energy Instruments, Advanced Bipolar Instruments, Ultrasonic Instruments

    4) By Distribution Channels: Direct Tender, Retail Sales, Online Sales, Other Channels

    5) By End User: Hospitals, Ambulatory And Surgical Centres, Academic And Research Institutes, Specialiaty Cancer Care Centre, Other End Users

    Subsegments:

    1) By Thoracotomy: Lobectomy, Pneumonectomy, Segmentectomy, Wedge Resection

    2) By Minimally Invasive Surgeries: Video-Assisted Thoracoscopic Surgery (VATS), Robotic-Assisted Surgery

    What Trends Are Influencing The Future Of The Lung Cancer Surgery Market?

    Leading companies in the lung cancer surgery market are prioritizing the development of innovative technologies, such as robotic-assisted surgeries, to improve surgical accuracy, shorten recovery periods, and enhance patient outcomes. Robotic-assisted surgeries are defined as minimally invasive procedures carried out using robotic systems controlled by surgeons, aiming to boost precision, lessen complications, and better patient rehabilitation results. For instance, in March 2025, Johnson & Johnson MedTech, a US-based medical devices and technology company, announced the regulatory clearance of MONARCH QUEST under U.S. 510(k). The MONARCH QUEST robotic-assisted bronchoscopy platform provides superior reach and stability to access small, hard-to-reach lung nodules, thus improving the capability to diagnose lung cancer in its earlier stages. Its advanced maneuverability and integration with imaging technologies facilitate more accurate biopsies while minimizing patient discomfort. Designed to expand procedural capabilities and streamline workflow, the platform supports increased clinical confidence and consistency across a broader array of bronchoscopic procedures.

    Which Industry Players Are Present In The Lung Cancer Surgery Market?

    Major companies operating in the lung cancer surgery market are Johnson And Johnson, Medtronic plc, Fujifilm Holdings Corporation, B Braun Melsungen AG, Olympus Corporation, Intuitive Surgical Inc, Teleflex Incorporated, Karl Storz SE, Lepu Medical Technology Beijing Co Ltd, Ambu AS, KLS Martin Group, Richard Wolf GmbH, Ethicon Inc, Ackermann Instrument GmbH, Scanlan International Inc, Sontec Instruments Inc, Covidien LLC, Stryker Corporation, Smith And Nephew plc, CONMED Corporation, Erbe Elektromedizin GmbH

    Access The Complete Lung Cancer Surgery Market Report:

    https://www.thebusinessresearchcompany.com/report/lung-cancer-surgery-global-market-report

    Which Region Holds The Largest Share In The Lung Cancer Surgery Market?

    North America was the largest region in the lung cancer surgery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer surgery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Lung Cancer Surgery Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=25816&type=smp

    Browse Through More Reports Similar to the Global Lung Cancer Surgery Market 2026, By The Business Research Company

    Lung Cancer Diagnostic And Screening Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

    Non Small Cell Lung Cancer Nsclc Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

    Non Small Cell Lung Cancer Nsclc Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Lung Cancer Screening Market Insights Exploring Expansion Opportunities Through 2030

    Lung Cancer Screening Market Insights Exploring Expansion Opportunities Through 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Are The Forecasted Market Size Figures For The Lung Cancer Screening Market In 2026 And 2030?

    The lung cancer screening market has demonstrated robust expansion recently. Forecasts indicate its size will increase from $3.33 billion in 2025 to $3.65 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.6%. This historical growth is linked to factors such as a greater occurrence of lung cancer among older demographics, heightened understanding of the advantages of early detection, the development of diagnostic imaging facilities, advancements in CT imaging technology, and the implementation of screening protocols based on established guidelines.

    The lung cancer screening market is anticipated to experience substantial expansion in the coming years, projected to reach $5.24 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period is primarily driven by the rising implementation of AI-assisted diagnostic workflows, the broadening of population-based screening initiatives, an intensified focus on personalized risk assessment, escalating investments in technologies for early cancer detection, and greater healthcare policy endorsement for screening. Additionally, key trends anticipated for this period encompass the increasing uptake of low-dose CT screening programs, the growing incorporation of AI into imaging analysis, a sharpened focus on screening high-risk populations, the broadening of preventive oncology initiatives, and an elevated emphasis on the early detection of lung cancer.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27331&type=smp

    Which Growth Drivers Are Expected To Support The Lung Cancer Screening Market Forward?

    The projected increase in smoking rates is set to boost the expansion of the lung cancer screening market moving forward. Smoking is defined as the act of breathing in smoke from burning substances, most often tobacco, through the mouth and into the lungs. The surge in smoking rates is attributed to elevated stress levels, which cause more individuals to resort to smoking as a coping mechanism. Lung cancer screening plays a crucial role in addressing rising smoking rates by facilitating the early detection of health risks associated with smoking, thus motivating individuals to quit and contributing to broader public health endeavors aimed at reducing tobacco use. For instance, in October 2024, the Office for Health Improvement & Disparities, a UK-based government organisation, reported that the prevalence of current smokers within the routine and manual occupation group (aged 18 to 64) in 2023 was 19.5%. Therefore, the growing smoking rates are propelling the growth of the lung cancer screening market.

    Which Segment-Based Categories Are Covered In The Lung Cancer Screening Market?

    The lung cancer screening market covered in this report is segmented –

    1) By Diagnosis Type: Low Dose Spiral Computed Tomography Scan, Chest-X-Ray

    2) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

    3) By Age Group: 50 And Older, Below 50

    4) By End-User: Hospitals And Clinics, Diagnostic Centers, Other End-Users

    Subsegments:

    1) By Low Dose Spiral Computed Tomography Scan: Screening, Diagnostic, Follow-Up

    2) By Chest X-Ray: Posterior Anterior, Lateral, Portable

    Which Trends Are Contributing To Changes In The Lung Cancer Screening Market?

    Major companies operating in the lung cancer screening market are concentrating on developing advanced solutions, such as normal flagging, to enhance diagnostic precision, reduce false positives, and improve the early identification of cancerous nodules. Normal flagging refers to a technological feature in lung cancer screening that automatically identifies and marks scans without abnormal findings, assisting in prioritizing cases that require further review. For instance, in May 2025, Lunit Inc., a South Korea-based medical technology company, unveiled INSIGHT CXR4, its next-generation artificial intelligence (AI)-powered chest X-ray analysis solution, which is now CE MDR-certified for deployment across Europe. Engineered to aid radiologists with improved diagnostic accuracy and workflow efficiency, the solution identifies 12 chest abnormalities, including lung nodules, pneumonia, and acute bone fractures, and integrates features like current-prior image comparison to support early disease detection and clinical decision-making.

    Which Organizations Are Involved In The Lung Cancer Screening Market?

    Major companies operating in the lung cancer screening market are Abbott Laboratories Inc., Canon Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, Delfi Diagnostics Inc., Hologic Inc., Fujifilm Holdings Corporation, United Imaging Healthcare Co. Ltd., Samsung Medison Co. Ltd., Carestream Health Inc., Analogic Corporation, Toshiba Medical Systems Corporation

    Access The Complete Lung Cancer Screening Market Report:

    https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report

    Which Region Is The Dominant Market In The Lung Cancer Screening Market?

    North America was the largest region in the lung cancer screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Lung Cancer Screening Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=27331&type=smp

    Browse Through More Reports Similar to the Global Lung Cancer Screening Market 2026, By The Business Research Company

    Financial Fraud Detection Software Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/financial-fraud-detection-software-global-market-report

    Payment Monitoring Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/payment-monitoring-global-market-report

    Ecommerce Fraud Detection And Prevention Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/ecommerce-fraud-detection-and-prevention-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Lung Cancer Liquid Biopsy Market Developments Influencing Industry Expansion Through 2030

    Lung Cancer Liquid Biopsy Market Developments Influencing Industry Expansion Through 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Much Larger Will The Lung Cancer Liquid Biopsy Market Become By 2030 Compared To 2026?

    The lung cancer liquid biopsy market has witnessed rapid growth in recent years. Its value is projected to rise from $1.12 billion in 2025 to $1.31 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.0%. Several factors contributed to its historical expansion, including increasing lung cancer incidence rates, the limitations inherent in tissue biopsy procedures, advancements within molecular diagnostics, the widespread availability of circulating biomarker technologies, and the overall growth in oncology research activities.

    The lung cancer liquid biopsy market size is projected for significant expansion in the coming years. This market is anticipated to reach $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.7%. Factors driving this growth during the forecast period include the increasing demand for precision oncology solutions, the broadening of liquid biopsy clinical applications, the rising adoption of companion diagnostics, the expanding integration of AI-driven data analysis, and an intensified focus on early cancer screening programs. Key trends identified for the forecast period encompass the increasing acceptance of non-invasive diagnostic techniques, the growing utilization of NGS-based liquid biopsy tests, an escalating demand for early cancer detection, the expansion of personalized oncology diagnostics, and improved integration of bioinformatics platforms.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

    What Influential Factors Are Boosting The Lung Cancer Liquid Biopsy Market Demand?

    The rising occurrence of lung cancer is expected to propel the future growth of the lung cancer liquid biopsy market. Lung cancer is a medical condition defined by the uncontrolled multiplication of abnormal cells in the lungs, often triggered by smoking and environmental exposures. The primary reason for the increase in lung cancer cases is ongoing tobacco use, as smoking introduces carcinogens into the lungs that stimulate abnormal cell development. Lung cancer liquid biopsy aids by identifying cancer-related genetic mutations and tumor DNA from a blood sample, which enables early diagnosis, selection of suitable treatment, and monitoring of disease advancement or response to therapy. For instance, in January 2023, according to a report published by the American Cancer Society (ACS), a U.S.-based nonprofit organization, it was estimated that in 2023, 238,340 individuals, including 117,550 men and 120,790 women, would be diagnosed with lung cancer, and 127,070 people are expected to die from the disease. Therefore, the increasing incidence of lung cancer is driving the growth of the lung cancer liquid biopsy market.

    What Are The Major Segment Categories Within The Lung Cancer Liquid Biopsy Market?

    The lung cancer liquid biopsy market covered in this report is segmented –

    1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

    2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

    3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

    4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

    5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

    Subsegments:

    1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

    2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

    3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

    What Trends Are Shaping The Lung Cancer Liquid Biopsy Market Structure?

    Major companies in the lung cancer liquid biopsy market are concentrating on advancing technologies, such as blood-based lung cancer screening tests, to improve early detection capabilities, enhance diagnostic precision, and allow for non-invasive, continuous monitoring of tumor progression and treatment outcomes. A blood-based lung cancer screening test represents a non-invasive method that examines biomarkers in the bloodstream to identify lung cancer at an early stage. For instance, in October 2023, DELFI Diagnostics Inc., a US-based biotechnology firm, introduced FirstLook Lung, a blood-based liquid biopsy test specifically developed to assist in the early detection of lung cancer. This test utilizes fragmentomics to pinpoint early lung cancer with high sensitivity and a 99.8% negative predictive value, providing an accessible and convenient initial step for at-risk individuals. Its aim is to boost early detection, increase screening participation, and help channel additional imaging resources to those who would most likely benefit.

    Who Are The Firms Contributing To The Lung Cancer Liquid Biopsy Market Ecosystem?

    Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

    Access The Complete Lung Cancer Liquid Biopsy Market Report:

    https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

    Which Area Represents The Largest Portion Of The Lung Cancer Liquid Biopsy Market?

    North America was the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Lung Cancer Liquid Biopsy Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=24593&type=smp

    Browse Through More Reports Similar to the Global Lung Cancer Liquid Biopsy Market 2026, By The Business Research Company

    Lung Cancer Diagnostic And Screening Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

    Liquid Biopsy Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

    Lung Cancer Drugs Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Lung Cancer Diagnostic And Screening Market Size Forecast To Achieve $4.03 Billion By 2030 With 9.6% CAGR

    Lung Cancer Diagnostic And Screening Market Size Forecast To Achieve $4.03 Billion By 2030 With 9.6% CAGR

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Growth In Market Value Is Anticipated For The Lung Cancer Diagnostic And Screening Market Between 2026 And 2030?

    The market size for lung cancer diagnostics and screening has experienced robust expansion over recent years. Projections indicate it will expand from $2.56 billion in 2025 to reach $2.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. This historical growth can be ascribed to several factors, including the significant prevalence of smoking-related lung cancer, the extensive adoption of chest x-ray and ct imaging, the expansion of hospital-based diagnostic infrastructure, a heightened awareness regarding early lung cancer detection, and the rise of biopsy-based diagnostic confirmation.

    The market for lung cancer diagnostics and screening is anticipated to experience substantial expansion over the coming years. This market is projected to reach $4.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. Several factors are expected to drive this growth during the forecast period, including the broadening of national lung cancer screening programs, the wider uptake of low-dose CT screening, an increasing need for biomarker and blood-based tests, greater healthcare spending on oncology diagnostics, and enhanced availability of diagnostic imaging facilities. Key trends anticipated within this period involve the increasing embrace of early lung cancer screening initiatives, the expanded application of advanced imaging and biomarker testing, a heightened emphasis on screening high-risk demographics, the proliferation of non-invasive diagnostic methodologies, and the growing incorporation of multimodal diagnostic approaches.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

    Which Drivers Are Advancing The Lung Cancer Diagnostic And Screening Market Growth?

    The market for lung cancer diagnosis and screening is anticipated to expand due to the rising occurrence of lung cancer. This malignant condition, characterized by the uncontrolled spread of atypical cells in lung tissues, manifests with symptoms like coughing, chest pain, and breathing difficulties. Diagnostic and screening procedures for lung cancer enable early detection of the illness in patients through diverse tests, such as incisional biopsy and bronchoscopy. An illustrative example from January 2023, based on data from the American Cancer Society, a US-based government organization, indicated that the United States saw approximately 238,340 new cases of lung cancer (comprising 117,550 in men and 120,790 in women). Additionally, 127,070 lung cancer deaths were reported (with 67,160 affecting men and 59,910 affecting women). Consequently, the increased prevalence of lung cancer is a key factor propelling the expansion of the lung cancer diagnostic and screening market.

    How Is The Lung Cancer Diagnostic And Screening Market Distributed Across Key Segments?

    The lung cancer diagnostic and screening market covered in this report is segmented –

    1) By Product: Instruments, Consumables And Accessories

    2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

    3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

    4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

    Subsegments:

    1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

    2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

    Which Trends Are Supporting The Evolution Of The Lung Cancer Diagnostic And Screening Market?

    Major companies in the lung cancer diagnostic and screening market are concentrating on developing blood-based tests that utilize machine learning, such as whole-genome machine learning, to provide accessible and convenient lung cancer screening and gain a competitive edge. Whole-genome machine learning refers to the application of machine learning algorithms for analyzing and interpreting comprehensive genetic information, encompassing an organism’s entire genome. For instance, in October 2023, DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, launched FirstLook Lung, a blood test employing whole-genome machine learning to analyze cell-free DNA fragments, thereby improving lung cancer screening with a 99.7% NPV. This test, designed for routine blood work, identifies individuals with potential lung cancer, including early-stage disease. Addressing low LDCT screening uptake, the test aims to improve population health.

    Which Key Players Are Active In The Lung Cancer Diagnostic And Screening Market?

    Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

    Access The Complete Lung Cancer Diagnostic And Screening Market Report:

    https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

    Which Region Commands The Largest Share Of The Lung Cancer Diagnostic And Screening Market?

    North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Lung Cancer Diagnostic And Screening Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp

    Browse Through More Reports Similar to the Global Lung Cancer Diagnostic And Screening Market 2026, By The Business Research Company

    Cancer Diagnostics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Respiratory Disease Testing Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

    Lung Cancer Drugs Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Low-Grade Glioma Market Forecast Covering Industry Demand And Market Evolution

    Low-Grade Glioma Market Forecast Covering Industry Demand And Market Evolution

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Expected Market Value Outlook For The Low-Grade Glioma Market Through 2030?

    The low-grade glioma market has experienced substantial expansion in recent times. It is projected to increase from $1.47 billion in 2025 to $1.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.9%. Historically, this growth can be ascribed to several factors, including developments in neuroimaging technologies, enhanced survival rates for low-grade glioma patients, a rise in neurosurgical interventions, increased public knowledge regarding brain tumor symptoms, and the proliferation of oncology treatment facilities.

    The low-grade glioma market is anticipated to exhibit substantial growth in the upcoming years, expanding to $1.94 billion by 2030, with a compound annual growth rate (CAGR) of 5.6%. This projected growth throughout the forecast period can be attributed to an increased emphasis on molecular tumor profiling, rising investments in targeted oncology drugs, a growing demand for less aggressive treatment alternatives, broadening access to specialized neuro-oncology care, and ongoing clinical trials for innovative therapies. Key trends during the forecast period involve a heightened focus on early diagnosis and consistent monitoring, increasing adoption of targeted drug therapies, a growing preference for multimodal treatment approaches, the expansion of personalized treatment planning, and the emergence of enhanced long-term disease management strategies.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

    What Primary Factors Are Fueling The Expansion Of The Low-Grade Glioma Market?

    The anticipated increase in brain tumor occurrences is set to drive expansion within the low-grade glioma market in the future. Brain tumors are characterized by anomalous cell proliferation within the brain or adjacent regions, potentially being either non-cancerous or cancerous. This surge in brain tumor cases stems from contributors like heightened radiation exposure, environmental contaminants, genetic susceptibility, and the natural aging process. Low-grade glioma treatment benefits brain tumor patients through the application of sophisticated diagnostic methods and specific therapies, including surgery, radiation, and chemotherapy. These interventions are vital for decelerating tumor advancement, safeguarding neurological capabilities, and enhancing patient prognosis, thereby emphasizing the critical importance of prompt identification and tailored care for handling other brain tumors exhibiting comparable growth profiles. As an illustration, in October 2025, figures from Cancer Australia, a government body based in Australia, indicated that in 2023, Australia registered 1,597 brain cancer fatalities (comprising 956 men and 641 women). Projections for 2025 suggest a modest increase to 1,639 deaths (including 979 men and 660 women). The projected likelihood of succumbing to brain cancer by age 85 in 2025 stands at 1 in 195 (0.51%), with males facing a higher risk of 1 in 165 (0.61%) and females a lower risk of 1 in 240 (0.42%). Consequently, the increasing occurrence of brain tumors is a primary impetus for the expansion of the low-grade glioma market.

    How Does Segment Analysis Break Down The Low-Grade Glioma Market Structure?

    The low-grade glioma market covered in this report is segmented –

    1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

    2) By Treatment: Surgery, Chemotherapy, Radiation

    3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

    Subsegments:

    1) By Trametinib: MEK Inhibitor Monotherapy, Combination Therapy (with BRAF Inhibitors)

    2) By Dabrafenib: BRAF V600E–Mutant Low-Grade Glioma, Combination Therapy (with MEK Inhibitors)

    3) By Ivosidenib: IDH1-Mutant Low-Grade Glioma, Oral Targeted Monotherapy

    4) By Mirdametinib: NF1-Associated Low-Grade Glioma, MEK Inhibitor Monotherapy

    What Trends Are Affecting The Growth Of The Low-Grade Glioma Market?

    Major companies operating in the low-grade glioma market are focusing on the integration of combination therapies and targeted treatment approaches, including genetic alteration drugs, to gain a competitive advantage and enhance the care of children with low-grade glioma. Genetic alteration drugs represent targeted therapies engineered to modify or inhibit specific genetic mutations or cellular abnormalities, thereby assisting in the treatment of diseases such as cancer by blocking the pathways responsible for uncontrolled cell growth. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, launched Tovorafenib (Ojemda) after securing accelerated FDA approval. This targeted therapy is intended for children aged six months and older with unresectable or recurrent low-grade glioma (LGG) that carries BRAF gene alterations. Offering a convenient once-weekly oral treatment, it addresses a crucial need for pediatric LGG patients who have had limited prior treatment options.

    Who Are The Leading Firms Participating In The Low-Grade Glioma Market?

    Major companies operating in the low-grade glioma market are F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc

    Access The Complete Low-Grade Glioma Market Report:

    https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

    Which Region Accounts For The Highest Share Of The Low-Grade Glioma Market?

    North America was the largest region in the low-grade glioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Low-Grade Glioma Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp

    Browse Through More Reports Similar to the Global Low-Grade Glioma Market 2026, By The Business Research Company

    Respiratory Devices And Equipment Therapeutic Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

    Respiratory Disease Drugs Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

    Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Lower Respiratory Tract Therapeutics Market Trends And Growth Outlook Across The 2026–2030 Forecast Period

    Lower Respiratory Tract Therapeutics Market Trends And Growth Outlook Across The 2026–2030 Forecast Period

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Will The Market Value Of The Lower Respiratory Tract Therapeutics Market Increase Between 2026 And 2030?

    The lower respiratory tract therapeutics market size has experienced strong growth in recent years. It is projected to expand from $38.84 billion in 2025 to $41.94 billion by 2026, at a compound annual growth rate (CAGR) of 8.0%. The historical growth in this market can be attributed to factors such as the increasing prevalence of asthma and copd, a high incidence of lower respiratory infections, the widespread use of antibiotics and bronchodilators, rising air pollution levels, and the expansion of hospital-based respiratory care.

    The lower respiratory tract therapeutics market size is projected to experience substantial expansion in the coming years. It is expected to grow to $57.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period can be attributed to an aging global population, increasing tobacco consumption and exposure to pollutants, heightened awareness of early respiratory disease treatment, improved healthcare access in emerging economies, and the expansion of outpatient and homecare respiratory therapies. Significant trends for the forecast period include the rising burden of chronic respiratory diseases, a greater focus on long-term disease management, an increasing demand for combination drug therapies, the expansion of respiratory care services for aging populations, and the growing adoption of home-based respiratory treatments.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12591&type=smp

    Which Strategic Drivers Are Supporting The Lower Respiratory Tract Therapeutics Market Development?

    The lower respiratory tract therapeutics market is expected to expand due to the increasing prevalence of respiratory diseases. Respiratory diseases are medical conditions affecting the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Lower respiratory tract therapeutics are primarily utilized for the early detection and diagnosis of such conditions, enabling earlier treatment and management. This can help prevent the disease from progressing and is also crucial for controlling the spread of infectious respiratory diseases while reducing the risk of complications. For example, in October 2024, the National Asthma Council, an Australia-based non-profit organization, reported that in 2023, Australia registered 474 asthma-related deaths, comprising 325 females and 149 males. This number is nearly identical to the 473 asthma-related deaths reported in 2022, indicating a consistent trend in asthma mortality over both years. Thus, the rising incidence of respiratory diseases will drive the lower respiratory tract therapeutics market.

    What Segment Types Are Included In The Lower Respiratory Tract Therapeutics Market Analysis?

    The lower respiratory tract therapeutics market covered in this report is segmented –

    1) By Disease Type: Asthma, Chronic Obstructive Pulmonary Disease, Pneumonia, Tuberculosis, Bronchitis, Other Diseases

    2) By Drug Class: Antibiotics, Non-Steroidal Anti-Inflammatory Drug, Cough Suppressant, Other Drug Classes

    3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    Subsegments:

    1) By Asthma: Allergic Asthma, Non-allergic Asthma

    2) By Chronic Obstructive Pulmonary Disease (COPD): Chronic Bronchitis, Emphysema

    3) By Pneumonia: Bacterial Pneumonia, Viral Pneumonia

    4) By Tuberculosis: Drug-sensitive Tuberculosis, Drug-resistant Tuberculosis

    5) By Bronchitis: Acute Bronchitis, Chronic Bronchitis

    6) By Other Diseases: Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension

    Which Trends Are Influencing The Direction Of The Lower Respiratory Tract Therapeutics Market?

    Major companies in the lower respiratory tract therapeutics market are concentrating on innovative offerings, such as triple combination drugs for managing COPD, to increase their market revenues. Triple combination therapy for COPD involves three inhaled medications: long-acting muscarinic antagonists (LAMA), long-acting beta-agonists (LABA), and inhaled corticosteroids (ICS). For instance, Lupin Limited, an India-based pharmaceutical company, launched Vilfuro-G in November 2023. This product is offered in a single fixed dose strength, with a recommended once-daily administration. The introduction of Vilfuro-G is expected to significantly enhance the lives of COPD patients and broaden Lupin’s respiratory product portfolio, showcasing the company’s dedication to providing cutting-edge treatment choices for patients and medical professionals. Vilfuro-G is the unique fixed-dose combination (FDC) specifically designed to combine glycopyrronium bromide, vilanterol, and fluticasone furoate for the long-term treatment and management of moderate to severe COPD.

    Which Companies Are Engaged In The Lower Respiratory Tract Therapeutics Market Environment?

    Major companies operating in the lower respiratory tract therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Menarini Group, Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Orion Corporation, Sunovion Pharmaceuticals Inc., Innoviva Inc., Insmed Incorporated, Vectura Group plc, Theravance Biopharma Inc., Verona Pharma plc, Circassia Pharmaceuticals plc

    Access The Complete Lower Respiratory Tract Therapeutics Market Report:

    https://www.thebusinessresearchcompany.com/report/lower-respiratory-tract-therapeutics-global-market-report

    Which Region Is The Primary Market For The Lower Respiratory Tract Therapeutics Market?

    North America was the largest region in the lower respiratory tract therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lower respiratory tract therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Lower Respiratory Tract Therapeutics Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=12591&type=smp

    Browse Through More Reports Similar to the Global Lower Respiratory Tract Therapeutics Market 2026, By The Business Research Company

    Adult Malignant Glioma Therapeutics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

    Glioblastoma Multiforme Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

    Pontine Glioma Drugs Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/pontine-glioma-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model